Paediatric Drug Development Regulatory Pathway Planner

Regulatory affairs and clinical teams at pharmaceutical companies developing drugs with potential paediatric use need to design a Paediatric Study Plan (PIP in EU) or Paediatric Investigation Plan (PIP) / Pediatric Study Plan (PSP in US) that satisfies EMA PDCO and FDA requirements while aligning to the commercial programme timeline.